Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed Glioblastoma

Exclusion Criteria

• •Meningeal carcinomatosis or spinal compression
• •Patients who have previously received chemotherapy, targeted therapy, or anti-angiogenesis
• •Active, known, or suspected autoimmune disease
• •Severe allergy to anlotinib or temozolomide
• •Patient having acute hepatitis virus infection, active tuberculosis, or other acute infectious diseases
• •Uncontrolled mental disorders
• •High risk of bleeding
• •Severe cardiovascular disease: myocardial ischemia or myocardial infarction above grade II, poorly controlled arrhythmias (including men with QTc interval ≥ 450 ms, women ≥ 470 ms), according to NYHA criteria; grades III to IV Insufficient function, or cardiac color Doppler ultrasound examination indicates left ventricular ejection fraction (LVEF) \<50%
• •Contraindicated for MRI examination
• •Recipient of live vaccine prior to the first dose of anlotinib
• •Ready for or previously received organ transplantation